File Download

There are no files associated with this item.

Supplementary

Conference Paper: Bone and renal safety Are improved in chronic HBV patients switched to tenofovir alafenamide after either 2 or 3 years of prior tenofovir disoproxil fumarate treatment.

TitleBone and renal safety Are improved in chronic HBV patients switched to tenofovir alafenamide after either 2 or 3 years of prior tenofovir disoproxil fumarate treatment.
Other TitlesBone and Renal Safety Improvements in CHB Patients Switched to Tenofovir Alafenamide(TAF) after Tenofovir Disoproxil Fumarate(TDF) Treatment
Authors
Seto, WKW
Issue Date2019
Citation
Liver Week, Korean Association for the Study of the Liver, Busan, Korea, 20-22 June 2019 How to Cite?
DescriptionFree Paper Session 1 [HBV] - abstract no. 138
Persistent Identifierhttp://hdl.handle.net/10722/272422

 

DC FieldValueLanguage
dc.contributor.authorSeto, WKW-
dc.date.accessioned2019-07-20T10:42:00Z-
dc.date.available2019-07-20T10:42:00Z-
dc.date.issued2019-
dc.identifier.citationLiver Week, Korean Association for the Study of the Liver, Busan, Korea, 20-22 June 2019-
dc.identifier.urihttp://hdl.handle.net/10722/272422-
dc.descriptionFree Paper Session 1 [HBV] - abstract no. 138-
dc.languageeng-
dc.relation.ispartofLiver Week, Korean Association for the Study of the Liver-
dc.titleBone and renal safety Are improved in chronic HBV patients switched to tenofovir alafenamide after either 2 or 3 years of prior tenofovir disoproxil fumarate treatment.-
dc.title.alternativeBone and Renal Safety Improvements in CHB Patients Switched to Tenofovir Alafenamide(TAF) after Tenofovir Disoproxil Fumarate(TDF) Treatment-
dc.typeConference_Paper-
dc.identifier.emailSeto, WKW: wkseto@hku.hk-
dc.identifier.authoritySeto, WKW=rp01659-
dc.identifier.hkuros299507-

Export via OAI-PMH Interface in XML Formats

OR

Export to Other Non-XML Formats